# A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

> **NCT06591598** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 51 (actual)

## Conditions studied

- Diabetic Macular Edema
- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Aflibercept (BAY86-5321, Eylea)

## Key facts

- **NCT ID:** NCT06591598
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-02
- **Primary completion:** 2025-10-14
- **Final completion:** 2025-10-14
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06591598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06591598, "A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06591598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*